Bausch+Lomb IPO Presentation Deck

...and creates a distinct advantage among eye care competitors³ Vision Care Consumer Surgical Ophthalmic Pharmaceuticals Diversified BAUSCH + LOMB Alcon Johnson Johnson BAUSCH+LOMB Alcon 2 1. Announced acquisition of distribution rights for Simbrinza in April 2021 2. Announced plan to separate consumer division on November 12, 2021 3. See Slide 2 for further information about comparable information. Vision Care CooperVision Focus Areas ZEISS Surgical HOYA Rayner Ophthalmic Pharmaceuticals Our robust and synergistic product portfolio allows us to build strong brand loyalty, engage with patients and consumers throughout the entire continuum of their eye health needs, and have a compelling offering for our physicians and retailers REGENERON Allergan & NOVARTIS 15

View entire presentation